Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

IGCS 2012

13 - 16 Oct 2012

Geneva Palexpo, Geneva, Switzerland

Effectiveness of PARP inhibitors in ovarian cancer

Prof Jonathan Ledermann - University College London, UK

Effectiveness of PARP inhibitors in ovarian cancer ( Prof Jonathan Ledermann - University College London, UK )

Issues in sentinel node mapping in endometrial and vulva cancer

Prof Henry Kitchener – Manchester University, UK

Issues in sentinel node mapping in endometrial and vulva cancer ( Prof Henry Kitchener – Manchester University, UK )

Complications in surgical approaches due to obesity

Dr Paola Gehrig – University of North Carolina, Chapel Hill, USA

Complications in surgical approaches due to obesity ( Dr Paola Gehrig – University of North Carolina, Chapel Hill, USA )

Radical hysterectomy of cervical cancer

Dr Shingo Fujii – Kitano Hospital, Osaka, Japan

Radical hysterectomy of cervical cancer ( Dr Shingo Fujii – Kitano Hospital, Osaka, Japan )

Retrospective study on adjuvant therapy in vulva cancer

Prof Sven Mahner - University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Retrospective study on adjuvant therapy in vulva cancer ( Prof Sven Mahner - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

Phase III HECTOR study: recurring platinum sensitive ovarian cancer

Prof Sven Mahner - University Medical Center Hamburg-Eppendorf , Hamburg, Germany

Phase III HECTOR study: recurring platinum sensitive ovarian cancer ( Prof Sven Mahner - University Medical Center Hamburg-Eppendorf , Hamburg, Germany )

GOG 209 study: optimal management of advanced endometrial cancer

Prof David Miller – University of Texas Southwestern Medical Centre, Dallas, USA

GOG 209 study: optimal management of advanced endometrial cancer ( Prof David Miller – University of Texas Southwestern Medical Centre, Dallas, USA )

AURELIA trial, palliative chemotherapy with bevacizumab in resistant, recurrent ovarian cancer

Dr Gunnar Kristensen – Norwegian Radium Hospital, Oslo, Norway

AURELIA trial, palliative chemotherapy with bevacizumab in resistant, recurrent ovarian cancer ( Dr Gunnar Kristensen – Norwegian Radium Hospital, Oslo, Norway )

The Cancer Genome Atlas and high grade serous ovarian cancer

Dr Andrew Berchuck – Duke University Medical Center, Durham, USA

The Cancer Genome Atlas and high grade serous ovarian cancer ( Dr Andrew Berchuck – Duke University Medical Center, Durham, USA )

Benefits of nomogram versus staging in cervical cancer

Dr Stephen Polterauer – Medical University of Vienna, Austria

Benefits of nomogram versus staging in cervical cancer ( Dr Stephen Polterauer – Medical University of Vienna, Austria )

Gestational trophoblastic disease tumours in high risk patients

Dr Michael Seckl – Charing Cross Hospital, Imperial College London, UK

Gestational trophoblastic disease tumours in high risk patients ( Dr Michael Seckl – Charing Cross Hospital, Imperial College London, UK )

Late effects of treatment in gynaecological cancers

Dr Remi Nout – Leiden University Medical Center, Netherlands

Late effects of treatment in gynaecological cancers ( Dr Remi Nout – Leiden University Medical Center, Netherlands )

Staging in endometrial cancer and sentinel node mapping

Dr Charles Levenback – MD Anderson Cancer Center, Houston, TX, USA

Staging in endometrial cancer and sentinel node mapping ( Dr Charles Levenback – MD Anderson Cancer Center, Houston, TX, USA )

OCTAVIA trial: bevacizumab and paclitaxel treatment for ovarian cancer

Dr Antonio Gonzalez-Martin – MD Anderson Cancer Center, Madrid, Spain

OCTAVIA trial: bevacizumab and paclitaxel treatment for ovarian cancer ( Dr Antonio Gonzalez-Martin – MD Anderson Cancer Center, Madrid, Spain )

State of PARP inhibitors and anti-angiogenics

Prof Stan Kaye – Royal Marsden Hospital, London, UK

State of PARP inhibitors and anti-angiogenics ( Prof Stan Kaye – Royal Marsden Hospital, London, UK )

Study of ovarian cancer and endometriosis sub-fertility

Prof Curt Burger – Erasmus University, Rotterdam, Netherlands

Study of ovarian cancer and endometriosis sub-fertility ( Prof Curt Burger – Erasmus University, Rotterdam, Netherlands )

New therapies to treat advanced endometrial cancer

Prof Gini Fleming – University of Chicago Medical Center, Illinois, USA

New therapies to treat advanced endometrial cancer ( Prof Gini Fleming – University of Chicago Medical Center, Illinois, USA )

Defining and advancing individualised medicine

Prof Anil Sood – MD Anderson Cancer Centre, Houston, USA

Defining and advancing individualised medicine ( Prof Anil Sood – MD Anderson Cancer Centre, Houston, USA )

Effects of early ovarian cancer screening

Dr Ed Pavlik – University of Kentucky, Lexington, USA

Effects of early ovarian cancer screening ( Dr Ed Pavlik – University of Kentucky, Lexington, USA )

Sexual health during and after ovarian cancer treatment

Dr Susan Carr – Royal Women’s Hospital, Parkville, Australia

Sexual health during and after ovarian cancer treatment ( Dr Susan Carr – Royal Women’s Hospital, Parkville, Australia )

More from ecancer